BELLUS Health Inc. (BELLUS Health) is a development-focused healthcare company. The Company is focusing on products, which provides health solutions and address medical needs. The Company�s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product, which include KIACTA, BLU8499 and VIVIMIND. BELLUS Health� primary focus is on advancing KIACTA, a treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study. BELLUS Health is also developing BLU8499 a prodrug of tramiprosate. VIVIMIND is a natural health product designed to protect memory function. In September 2012, BELLUS Health entered into a license and distribution agreement with Lifenergy Biotech Corp. (Lifenergy), pursuant to which the Company granted Lifenergy distribution rights for VIVIMIND in Taiwan.